Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2006-03-24
Original market date: See footnote 1
2002-12-02
Product name:
VARIVAX III
DIN:
02246081
Product Monograph/Veterinary Labelling:
Date:
2023-11-28
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
MERCK CANADA INC
16750 Route Transcanadienne
Kirkland
Quebec
Canada
H9H 4M7
Class:
Human
Dosage form(s):
Powder For Solution
Route(s) of administration:
Subcutaneous
Number of active ingredient(s):
1
Schedule(s):
Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
80:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
J07BK01 VARICELLA, LIVE ATTENUATED
Active ingredient group (AIG) number:See footnote5
0165422001
| Active ingredient(s) | Strength |
|---|---|
| VARICELLA VIRUS LIVE ATTENUATED (OKA/MERCK STRAIN) | 1350 UNIT / 0.5 ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.